AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15500555
Drug: 5 MU
RxNorm normalized name: MULTISTIX 5 MULTIPLE TEST STRIP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 MU TIW of IFN alfa 2b for 4 weeks followed by IFN (5 MU TIW) plus ribavirin (1000/1200 mg/daily) for 48 weeks (group 2)
Trial: 11256836
Drug: Combined androgen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined androgen blockade with UFT (400 mg/day)
Trial: 10352494
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone dipropionate (BDP) therapy for 3 months
Trial: 10352494
Drug: Change in
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Change in FEV1% between baseline and post-treatment
Trial: 7655780
Drug: IL-2 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL-2 (3 x 10(6) IU/day subcutaneously for 4 weeks) plus melatonin (40 mg/day orally)
Trial: 29624832
Drug: Metacognitive Interpersonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metacognitive Interpersonal Therapy (MIT-G)
Trial: 29624832
Drug: Waiting list
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting list + Treatment as Usual (TAU)
Trial: 28467116
Drug: Combined self-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined self-administered foot massage and CBT
Trial: 25599690
Drug: Combined strategy
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined strategy intervention including printed information, treatment-compliance check cards, and text messages.
Trial: 16153217
Drug: Tadalafil 10
RxNorm normalized name: tadalafil 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 10 or 20 mg
Trial: 14690014
Drug: Levamisole (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamisole (80 mg every other day for 6 weeks) + rifampicin (600 mg/day) + doxycycline (200 mg/day) for 6 weeks
Trial: 14690014
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (rifampicin 600 mg/day + doxycycline 200 mg/day for 6 weeks)
Trial: 2069382
Drug: Loracarbef (LY163892)
RxNorm normalized name: Loracarbef
DrugBank: Loracarbef (DB00447)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loracarbef (LY163892) at 200 mg once daily (n = 53)
Trial: 2069382
Drug: Cefaclor at
RxNorm normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefaclor at 250 mg three times daily (n = 55)
Trial: 26931369
Drug: Gemcitabine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine and capecitabine combination chemotherapy with sequential telomerase GV1001 vaccine (n=18)
Trial: 26931369
Drug: Gemcitabine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine and capecitabine combination chemotherapy with concomitant telomerase GV1001 vaccine (n=24)
Trial: 26931369
Drug: Gemcitabine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine and capecitabine combination chemotherapy
Trial: 22905596
Drug: High-dose hypoallergenic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose hypoallergenic 6-grass pollen preparation (SCIT)
Trial: 17097812
Drug: Patients 1
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients 1 year after treatment initiation
Trial: 9366459
Drug: 0.25 microg
RxNorm normalized name: calcitriol 0.25 MICROGRAM In 1 CAPSULE ORAL CAPSULE, LIQUID FILLED [Rocaltrol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 microg x kg(‐1) x h(‐1) naloxone (low dose)
Trial: 9366459
Drug: 1 microg
RxNorm normalized name: Alpha 1 microglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 microg x kg(‐1) x h(‐1) naloxone (high dose)
Trial: 30711295
Drug: Immediate loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate loading of dental implants with bar overdentures (n=35)
Trial: 29537647
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogen (CEE, 0.625 mg/day)
Trial: 19155011
Drug: CEE (0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE (0.625 mg/day) plus medroxyprogesterone acetate (MPA, 2.5mg/day)
Trial: 15075543
Drug: Etanercept 25
RxNorm normalized name: etanercept 25 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept 25 mg, eight doses administered subcutaneously twice weekly beginning on day 4 of tuberculosis therapy
Trial: 10021962
Drug: 27-G Quincke
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 27-G Quincke needle
Trial: 10021962
Drug: 27-G Whitacre
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 27-G Whitacre needle
Trial: 31841136
Drug: Continued bivalirudin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued bivalirudin infusion after PCI
Trial: 31841136
Drug: No bivalirudin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No bivalirudin infusion after PCI
Trial: 21810165
Drug: Methylnaltrexone 12
RxNorm normalized name: methylnaltrexone 12 mg/0.6 mL subcutaneous kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylnaltrexone 12 mg subcutaneous daily for 4 weeks
Trial: 16686911
Drug: Triptan treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triptan treatment
Trial: 15560164
Drug: Efferent therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efferent therapy after medication and photomodification of the blood
Trial: 12670352
Drug: Desferrioxamine (DFX)
DrugBank: Deferoxamine (DB00746)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desferrioxamine (DFX) alone (40‐50 mg/kg/d s.c. over 8‐12 h, five times weekly)
Trial: 12670352
Drug: Combined DFX
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined DFX twice weekly and deferiprone (75 mg/kg/d)
Trial: 22385038
Drug: MicroPlaSter alpha
RxNorm normalized name: alpha tocopherol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MicroPlaSter alpha device (2 min cold atmospheric argon plasma treatment)
Trial: 22385038
Drug: MicroPlaSter beta
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MicroPlaSter beta device (2 min cold atmospheric argon plasma treatment)
Trial: 20332772
Drug: Venlafaxine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine (75 mg hora somni)
Trial: 18329226
Drug: Gay-specific cognitive-behavioral
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gay-specific cognitive-behavioral therapy (GCBT, n = 64)
Trial: 18329226
Drug: Gay-specific social
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gay-specific social support therapy (GSST, n = 64)
Trial: 16143248
Drug: Basiliximab (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basiliximab (20 mg)
Trial: 12756512
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg daidzein twice daily for 10 days
Trial: 10051505
Drug: Interferon (IFN)
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon (IFN) therapy with steroid priming
Trial: 8595083
Drug: Pyridoxine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridoxine (5 mg/kg body weight/day) for 4 weeks
Trial: 1709446
Drug: Single infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single infusion of gamma globulin (2 g/kg over 10 hours)
Trial: 1709446
Drug: Four daily
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four daily infusions of gamma globulin (400 mg/kg for four consecutive days)
Trial: 1709446
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (single infusion and four daily infusions)
Trial: 7027425
Drug: 600 mg/d
RxNorm normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/d antrafenine
Trial: 7027425
Drug: 3 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/d aspirin
Trial: 21649457
Drug: Decaffeinated green
RxNorm normalized name: (-)-EPIGALLOCATECHIN-3-O-GALLATE (EGCG) (CONSTITUENT OF POWDERED DECAFFEINATED GREEN TEA EXTRACT) [DSC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decaffeinated green tea extract (GTE) 1,500 mg daily for 16 weeks
Trial: 19234815
Drug: Midazolam, 0.025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam, 0.025 mg x kg(‐1)
Trial: 16720593
Drug: Statin use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin use with >1 defined daily dose
Trial: 16720593
Drug: Statin use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin use with >2 defined daily doses
Trial: 15448611
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg levobupivacaine with 25 microg fentanyl
Trial: 15448611
Drug: Half the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half the dose of levobupivacaine and fentanyl (1.25 mg levobupivacaine with 12.5 microg fentanyl)
Trial: 11268266
Drug: gemfibrozil, 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemfibrozil, 1200 mg/d (n = 1264)
Trial: 9495299
Drug: FGF‐I (0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FGF‐I (0.01 mg/kg body weight)
Trial: 2567793
Drug: Loxiglumide (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loxiglumide (oral administration, 800 mg three times daily for 7 days)
Trial: 2567793
Drug: Loxiglumide (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loxiglumide (oral administration, 30 min before test meal)
Trial: 107583
Drug: Continuous sodium
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous sodium fluoride treatment
Trial: 107583
Drug: Intermittent sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent sodium fluoride treatment
Trial: 30774322
Drug: Higher-dose physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-dose physical activity (180 minutes/week)
Trial: 30774322
Drug: Lower-dose physical
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-dose physical activity (120 minutes/week)
Trial: 24433249
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy for insomnia (CBT‐I) consisting of sleep restriction, psychoeducation about sleep, stabilization of the circadian rhythm, and challenging and correcting sleep state misperception, in three to eight sessions.
Trial: 24433249
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU) consisting of pharmacological and supportive psychosocial treatment.
Trial: 18668363
Drug: E-T-CMF (epirubicin-alkylator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E-T-CMF (epirubicin-alkylator based adjuvant chemotherapy with paclitaxel)
Trial: 18668363
Drug: E-CMF (epirubicin-alkylator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E-CMF (epirubicin-alkylator based adjuvant chemotherapy without paclitaxel)
Trial: 25963190
Drug: Adjuvant hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adjuvant hormone therapy
Trial: 14989560
Drug: Granulocyte/macrophage colony
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte/macrophage colony stimulating factor (GM-CSF) at a dose of 10 microg/kg for 14 days
Trial: 10752807
Drug: BB-882 (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BB-882 (4 mg loading dose on the first day, followed by 96 mg/24 hrs for up to 120 hrs)
Trial: 1403212
Drug: Two sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two sequential reminder letters offering free influenza immunization without an appointment
Trial: 3890666
Drug: Topical 0.1%
RxNorm normalized name: adapalene topical 0.1% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.1% dexamethasone drops
Trial: 28953447
Drug: Rituximab maintenance
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab maintenance therapy (375 mg/m² every 2 months for 3 years)
Trial: 15966464
Drug: SPP301 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPP301 5 mg
Trial: 14681342
Drug: SPP301 >20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPP301 >20 mg
Trial: 14681342
Drug: SPP301 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPP301 50 mg
Trial: 14681342
Drug: SPP301 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPP301 100 mg
Trial: 15966464
Drug: SPP301 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPP301 (all doses)
Trial: 9443526
Drug: 1.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/kg i.v. naloxone
Trial: 8494665
Drug: Cephradine 500
RxNorm normalized name: cephradine 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephradine 500 mg twice daily for 5 days
Trial: 8494665
Drug: Amoxycillin 250
RxNorm normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxycillin 250 mg three times daily for 5 days
Trial: 8494665
Drug: Phenoxymethylpenicillin 250
RxNorm normalized name: phenoxymethylpenicillin
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenoxymethylpenicillin 250 mg four times daily for 5 days
Trial: 30161291
Drug: GSK2618960 (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2618960 (0.6 mg kg–1)
Trial: 30161291
Drug: GSK2618960 (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2618960 (2.0 mg kg–1)
Trial: 25907945
Drug: 8 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg/kg celecoxib (group A)
Trial: 25907945
Drug: 0.4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg/kg Sou‐Medrol (group B)
Trial: 21715516
Drug: Adequate-dairy (AD)
RxNorm normalized name: Beano Dairy Defense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adequate-dairy (AD) diet (3.5 daily servings)
Trial: 21715516
Drug: Low-dairy (LD)
RxNorm normalized name: Beano Dairy Defense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dairy (LD) diet (<0.5 daily servings)
Trial: 19340462
Drug: Gelatine sponge
RxNorm normalized name: Gelatin
DrugBank: Gelatin (DB11242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelatine sponge soaked with a 10 mg morphine hydrochloride solution placed in the iliac region for local opiate therapy.
Trial: 19340462
Drug: Intraoperatively centrally
RxNorm normalized name: Rauwolfia alkaloids, centrally acting antiadrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperatively centrally administered opiates injected into the contralateral gluteus maximus muscle for systemic therapy.
Trial: 14504943
Drug: Bovine colostrum
RxNorm normalized name: Bovine Colostrum
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bovine colostrum (BC) supplementation (60 g day(‐1))
Trial: 8150110
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human FSH (150 IU, SC, multiple doses)
Trial: 25817472
Drug: Midwife group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midwife group (misoprostol treatment)
Trial: 25817472
Drug: Physician group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician group (misoprostol treatment)
Trial: 17031012
Drug: RRR-alpha-tocopherol 100
RxNorm normalized name: RRR-alpha-tocopheryl acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RRR-alpha-tocopherol 100 mg/day
Trial: 17031012
Drug: RRR-alpha-tocopherol 400
RxNorm normalized name: RRR-alpha-tocopheryl acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RRR-alpha-tocopherol 400 mg/day
Trial: 17031012
Drug: RRR-alpha-tocopherol 200
RxNorm normalized name: RRR-alpha-tocopheryl acetate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RRR-alpha-tocopherol 200 mg/day
Trial: 10676922
Drug: Limited prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Limited prednisone treatment followed by WinRho SDF (anti-D) therapy
Trial: 8668663
Drug: Oral dose
RxNorm normalized name: Exactamed Oral Dose Syringe 35cc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose of FK506
Trial: 8668663
Drug: Intravenous dose
RxNorm normalized name: Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dose of FK506
Trial: 1979009
Drug: Doxacurium 0.037
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxacurium 0.037 mg kg‐1
Trial: 1979009
Drug: Doxacurium 0.075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxacurium 0.075 mg kg‐1
Trial: 1979009
Drug: Vecuronium 0.075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium 0.075 mg kg‐1
Trial: 1979009
Drug: Pancuronium 0.09
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancuronium 0.09 mg kg‐1
Trial: 1979009
Drug: High-dose doxacurium
RxNorm normalized name: Doxacurium
DrugBank: Doxacurium (DB01135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose doxacurium 0.075 mg kg‐1
Trial: 31142474
Drug: Tocilizumab (TOC)
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab (TOC) monotherapy
Trial: 21642603
Drug: Diluted 4.2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diluted 4.2% sodium bicarbonate (50 mL)
Trial: 21642603
Drug: 0.9% normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% normal saline (50 mL)
Trial: 19202222
Drug: Re-treatment with
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Re-treatment with pegylated interferon and ribavirin in group I (relapsers)
Trial: 19202222
Drug: Re-treatment with
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Re-treatment with pegylated interferon and ribavirin in group II (non responders, partial responders, breakthrough non responders)
Trial: 21711479
Drug: Tadalafil 20
RxNorm normalized name: tadalafil 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 20 mg on demand
Trial: 17227498
Drug: Tadalafil 20
RxNorm normalized name: tadalafil 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 20 mg three times per week
Trial: 9764785
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (800 IU daily) and Vitamin C (1000 mg daily)
Trial: 20059603
Drug: Novel agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel agents
Trial: 16961129
Drug: GliaSite brachytherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GliaSite brachytherapy (60 Gy dose administered to a 1-cm depth after resection)
Trial: 1607191
Drug: Lidocaine/prilocaine cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine/prilocaine cream (EMLA(R))
Trial: 25261599
Drug: Mindfulness Based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness Based Cognitive Therapy (MBCT) with formal home practice of at least 3 days a week
Trial: 19940856
Drug: Silver alginate
RxNorm normalized name: Care Touch Silver Alginate Wound Dressing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silver alginate (Algidex) patches
Trial: 18848350
Drug: Consistent bronchodilator
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consistent bronchodilator response (BDR)
Trial: 10813108
Drug: toremifene (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: toremifene (40 mg/day; n = 19)
Trial: 10813108
Drug: tamoxifen (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tamoxifen (20 mg/day; n = 25)
Trial: 1640148
Drug: Injection of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of methylprednisolone acetate plus local anaesthetic
Trial: 1640148
Drug: Control injection
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control injection of local anaesthetic
Trial: 31289885
Drug: Alcohol (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (low or moderate dosage)
Trial: 27067521
Drug: Endostatin (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endostatin (7.5 mg/m² weekly for 14 days), Paclitaxel (50 mg/m²), Carboplatin (2 mg/mL/min over 30 min) during chemoradiotherapy; followed by Endostatin (7.5 mg/m² for 14 days), Paclitaxel (150 mg/m²), Carboplatin (5 mg/mL/min every 3 weeks for 2 cycles) as consolidation treatment.
Trial: 27067521
Drug: Endostatin treatment
RxNorm normalized name: Pentostatin
DrugBank: Pentostatin (DB00552)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endostatin treatment